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Genomic analysis of prostate cancer has not answered key clinical questions such as ‘‘Which tumors are
likely to recur?’’ or ‘‘Which pathways should we target for treatment?’’ The study by Taylor et al., initiated
by the late William Gerald, published in this issue of Cancer Cell is a game changer.In the late 1990s and early years of this
century, genomic analysis of cancer
promised to revolutionize the way that
cancer is diagnosed and treated. There
were a series of innovative reports that
opened up a new world where one could
see that genomic characterization could
lead to better diagnostics and perhaps
even better strategies for treatment
(Golub et al., 1999; Perou et al., 1999). It
wasn’t long before this genomic approach
led to development of new diagnostic
tests that favorably impact the lives of
women with early-stage breast cancer
(Paik et al., 2004; van de Vijver et al.,
2002). Examination of a set of genes
initially pinpointed by genomic analysis
can inform a woman whether her tumor
is likely to recur and whether she might
benefit from postsurgical treatment with
chemotherapy. However, the genomic
approach— or more accurately, genome-
wide RNA expression profiling—was not
as successful with other common cancer
types, including prostate cancer.
One of the big problems in prostate
cancer that people were hoping to solve
was how to predict which patients with
early-stage prostate cancer would prog-
ress (Shariat et al., 2009). This problem
is similar to the problem in breast cancer
that was solved by genomic analysis,
but different in two major ways. One is
that the time to recurrence in prostate
cancer is usually much longer than it is
for breast cancer, and the other is that
unlike breast cancer, there isn’t a proven
regimen of chemotherapy that helps
prevent such recurrences. What needs
to happen in prostate cancer is to develop
a good predictive biomarker for recur-
rence that can pinpoint patients likely to
experience recurrences in a short enough
time frame to carry out clinical trials with
agents that might prevent them.The report by Taylor et al. (2010) in this
issue of Cancer Cell follows a trend being
set by cancer genome projects including
the Cancer Genome Atlas (TCGA) to
perform genomic analysis that integrates
genome-wide expression analysis with
both DNA copy-number analysis and
DNA sequencing. This integrated ap-
proach paid off in this case, as the authors
were able to test two classes of alter-
ations for their ability to predict recur-
rence, RNA expression profiling, and
DNA copy-number profiling. Unlike breast
cancer, in which RNA expression profiling
can predict recurrence, Taylor et al. found
that it could not predict recurrence in
prostate cancer, but that DNA copy-
number profiling could. Essentially what
they found was a group of prostate
tumors with extensive DNA copy-number
alterations that had a much shorter time to
recurrence than other tumors. If con-
firmed, this then would provide a molec-
ular diagnostic test to identify the patients
who will recur more rapidly and could
therefore be good candidates for clinical
trials testing new systemic treatments.
Additionally, another group of prostate
tumors that were essentially diploid
without any major DNA copy-number
alterations were largely recurrence free
during the 5 year period of clinical
follow-up. It is possible then to envision
an array CGH test being able to pinpoint
not only patients likely to recur quickly
but quite possibly ones who don’t even
need surgery. This could put more scien-
tific rigor into the decision to choose
watchful waiting, which is a course of
action not generally recommended in the
United States because of concerns of
recurrence.
Why does DNA copy-number profiling
work in prostate cancer to predict recur-
rence but RNA expression profiling doesCancer Cnot? It is worth noting here that DNA
copy-number profiling by array CGH has
previously been shown to predict recur-
rence in breast cancer (Hicks et al.,
2006), in a manner parallel to the situation
with prostate cancer. Thus, both RNA
expression profiling and DNA expression
profiling work for breast cancer. So the
real question is why doesn’t RNA expres-
sion profiling work for prostate cancer?
One possible answer is that there is only
a single type of normal cell that can
become a tumor-initiating cell in prostate
cancer and that in breast cancer there
are several and being able to capture
this information by expression profiling is
what really enables that test to work.
Clearly other answers are possible.
Despite remaining questions about the
underlying biology, having a promising
molecular test to pinpoint patients likely
to recur is a major step forward for finding
adjuvant chemotherapy treatments that
can be tested. Eventually, this will help
reduce prostate cancer mortality. This
brings us to another promising aspect of
this new study, which is the identification
of the key pathways that are altered
genetically in prostate cancer. The path-
ways ‘‘chosen’’ by the genetic alterations
that are driving cancer are among the best
ones to inhibit for therapy—particularly
if the property of oncogene addiction is
more general in the sense that diverse
genetic alterations affecting a single
pathway all lead to significant pathway
addiction. If this is the case, androgen
receptor (AR) signaling, PI3K signaling,
and RAF/MEK signaling are the key path-
ways to target on the basis of the findings
presented in Taylor et al. Their approach
to identifying which pathways are altered
is based on the TCGA approach of inte-
grating alterations in expression, DNA
copy number, and mutations. Notably,ell 18, July 13, 2010 ª2010 Elsevier Inc. 1
Figure 1. An Optimist’s View of the Translational Impact of the Taylor et al. Study
(A) depicts clinical implementation of an array CGH test to stratify newly diagnosed prostate cancer
patients into three subgroups, the subgroup in which tumors show extensive DNA copy-number alter-
ations and is highly enriched for patients who will have recurrences within five years, the subgroup that
have tumors without DNA copy-number alterations and may not even require surgery, and the remaining
subgroup that would probably need surgery but were not at high risk of relapse. (B) depicts the testing of
adjuvant treatments for high risk patients identified by array CGH. Priority would be given to inhibitors of
cancer pathways identified by genomic analysis.
Cancer Cell
Previewsthis is the first time that genetic alterations
affecting AR signaling have been de-
scribed in primary prostate cancer, thus
bringing together one of the most
fundamental aspects of the physiology
of prostate cancer with the underlying
genetic driver events. Although pathway
inhibitors are most likely to be first tested
on patients with late-stage disease, once
they pass that hurdle it is possible to envi-
sion their being tested in the adjuvant
setting along with surgery, with patients
selected by aCGH analysis (Figure 1).
From a genetic perspective, it is inter-
esting how this report revealed frequent
single-copy loss of major tumor sup-
pressors such as RB1, PTEN, and TP53,
whereas mutations in these genes were
largely absent except for a handful
of tumors harboring TP53 mutations.
Together with TCGA studies, haploinsuffi-2 Cancer Cell 18, July 13, 2010 ª2010 Elseviciency of these genes appears to be
a widespread means of dysregulating
key cancer pathways—any may in some
cases require cooperation of tumor
suppressor alterations within the same
cancer pathways, for example they noted
codeletion of CDKN2A/B together with
partial loss of RB1 (Taylor et al., 2010).
Another novel finding of this paper was
co-occurrence of the frequent TMPRSS2-
ERG gene fusion with three different
regions of copy-number alterations: one
harboring PTEN, one in TP53, and a novel
alteration implicating only three genes
(FOXP1,RYBP, and SHQ1). Therefore, we
can easily envision how in vivo and in vitro
functional assays, which have already
identified the cooperation between PTEN
and TMPRSS2-ERG (Carver et al., 2009;
King et al., 2009), will be applied to
expand our knowledge of core pathwayser Inc.of cancer and their relationship to thera-
peutic response.
It is a tribute to the late William Gerald
that he initiated this project with rigorous
standards for both the quality of the spec-
imens and the potential utility of the clin-
ical annotation. It’s also noteworthy that
a diverse set of clinical scientists, labora-
tory scientists, and computational scien-
tists worked together to fulfill his vision
and achieve this milestone in prostate
cancer research. And it is also clear that
cancer genomics—at least when it is
practiced on the level of Taylor et al.—still
has the potential to make solid and valu-
able contributions to the field of cancer.REFERENCES
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